AVALERE HEALTH
Avalere Health’s recently updated analysis of 2023 Medicare Current Beneficiary Survey data suggests that the Global Benchmark for Efficient Drug Pricing (GLOBE) Model would have a very limited impact on OOP costs. We found that:
Among fee-for-service (FFS) beneficiaries who used GLOBE-eligible drugs, less than 3,000 have standard Part B OOP cost-sharing exposure because they do not have supplemental insurance.
When accounting for the GLOBE Model’s application to approximately 25% of Part B FFS beneficiaries, this number falls to fewer than 700 beneficiaries.
Only approximately 0.0025% of all FFS beneficiaries would likely directly benefit from reductions in OOP cost liability under the finalized GLOBE rule.
Read more here.